Santen Pharmaceutical Co., Ltd., based in Osaka, Japan, has recently announced significant developments in its North American pharmaceutical sales business. The company has entered into out-licensing agreements and asset transfer agreements with two prominent US companies. These agreements are expected to bolster Santen’s presence in the region and drive growth.
Granting Exclusive Rights to Visiox Pharmaceuticals
One of the agreements involves glaucoma and ocular hypertension treatment, OMLONTI🄬. Santen has concluded a product licensing agreement with Visiox Pharmaceuticals, Inc., headquartered in New York, USA. As per the terms of the agreement, Santen will grant Visiox exclusive rights to manufacture and commercialize OMLONTI🄬 in the United States. In return, Santen will receive sales milestones, sales royalties, and other benefits from Visiox.
Strengthening the Portfolio with Harrow Health
Additionally, Santen has partnered with Harrow Health, Inc., based in Tennessee, USA, to further expand its product portfolio in the North American market. The agreement encompasses several eye care products, including Flarex 🄬 (an anti-inflammatory eye drop), Natacyn 🄬 (an anti-fungal eye drop), TobraDex 🄬 ST (an anti-inflammatory and antibacterial eye drop), and ZERVIATE (an anti-allergy eye drop).
Asset Transfer and Out-Licensing Agreements
Under the agreements, Santen will transfer ownership of Flarex🄬, Natacyn🄬, TobraDex🄬 ST, ZERVIATE🄬, and FRESHKOTE🄬, as well as the exclusive rights to manufacture and commercialize Verkazia🄬 in the United States and Canada, and Cationorm🄬 Plus in Canada. The recipient of these rights and products will be Harrow Health. In addition to the manufacturing and commercialization rights, Harrow Health will also make a lump-sum payment for the product transfer, as well as for Verkazia🄬 and Cationorm🄬 Plus. Furthermore, Harrow Health will be entitled to sales royalties and other related benefits.
Commitment to Growth and Patient Care
Santen Pharmaceutical remains steadfast in its commitment to enhancing profitability from a company-wide perspective and securing investments in research and development that cater to unmet medical needs. The company aims to further advance the development of promising pipelines, ultimately maximizing the value it brings to patients.
About Santen
A Vision for Global Impact
Santen Pharmaceutical is a specialized company focusing on ophthalmology. It conducts extensive research, development, sales, and marketing activities for ethical and over-the-counter pharmaceuticals and medical devices. With a global presence spanning over 60 countries and regions, Santen strives to make a difference in people’s lives.
World Vision for Happiness with Vision
The company’s core mission, encapsulated in its “WORLD VISION” initiative, is to promote happiness through vision. As a Social Innovator, Santen aims to connect technologies, organizations, and human resources worldwide, working toward an ideal world. By going beyond the traditional role of a pharmaceutical company, Santen leverages its 130-year history and scientific expertise to develop patient-centric ophthalmic medical solutions. The company aims to reduce social and economic challenges faced by individuals around the world due to visual impairments.
Sources: THX News & Santen Pharmaceutical Co., Ltd.
